xanomeline and trospium chloride

FDA Drug Profile — Cobenfy

xanomeline and trospium chloride is listed in the FDA National Drug Code directory with 13 NDC codes, marketed under brand name including Cobenfy. Available dosage forms: capsule, coated pellets, kit, capsule.

Drug details

Generic Name
xanomeline and trospium chloride
Brand Names
Cobenfy
Application Number
NDA216158
Sponsor
E.R. Squibb & Sons, L.L.C.
NDC Codes
13
Dosage Forms
CAPSULE, COATED PELLETS, KIT, CAPSULE
Routes
ORAL
Active Ingredients
XANOMELINE, TROSPIUM CHLORIDE, XANOMELINE TARTRATE

Indications and Usage

1 INDICATIONS AND USAGE COBENFY is indicated for the treatment of schizophrenia in adults. COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, indicated for the treatment of schizophrenia in adults. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.